<DOC>
	<DOCNO>NCT03101046</DOCNO>
	<brief_summary>This study compare biological activity cabazitaxel ( 6 cycle ) docetaxel ( 6 cycle ) metastatic castrate-resistant prostate cancer ( mCRPC ) patient docetaxel resistant mCPRC define ≥ 5CTCs/7.5ml 2 cycle docetaxel . Patients docetaxel resistant metastatic castration-resistant prostate cancer ( mCRPC ) base circulate tumor cell ( CTC ) enumeration ( patient ≥ 5CTCs/7.5ml docetaxel chemotherapy 2 cycle docetaxel ) receive either 6 additional cycle docetaxel 6 additional cycle cabazitaxel randomisation . A cohort patient docetaxel sensitive metastatic castration-resistant prostate cancer ( mCRPC ) base circulate tumor cell ( CTC ) enumeration ( patient ≥ 5CTCs/7.5ml docetaxel chemotherapy &lt; 5CTCs/7.5ml 2 cycle docetaxel ) receive 6 additional cycle docetaxel</brief_summary>
	<brief_title>Treatment Metastatic Castrate Resistant Prostate Cancer Patients According Circulating Tumor Cells Kinetic</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Written inform consent sign prior studyrelated procedure 2 . Adult men ≥ 18 year 3 . Histologically confirm prostate adenocarcinoma 4 . Metastatic disease evidence imaging ( bone scan , CT scan , MRI and/or PETcholine ) . 5 . Documented progressive disease receive continuous hormonal treatment LHRH agonist antagonist surgical castration ( least one visceral soft tissue metastatic lesion , include new lesion ) . Patient nonmeasurable disease must document rise PSA level appearance new lesion 6 . Effective castration assess testosterone level ≤ 50 ng/dl 7 . Patients performance status ECOG ≤ 2 ( Appendix 1 ) 8 . Patients affiliate social security scheme 1 . Prior chemotherapy metastatic prostate cancer except estramustine &lt; 1 year end adjuvant and/or neoadjuvant chemotherapy localize disease &lt; 1 year end chemotherapy de novo metastatic prostate cancer 2 . Prior isotope therapy , whole pelvic radiotherapy radiotherapy &gt; 30 % bone marrow , 3 . Less 1 month elapse prior treatment radiotherapy , surgery le 2 week previous hormonal treatment except LHRH agonists/antagonists ( continue ) . Patients may treat bisphosphonates prior study entry pursue , 4 . History brain metastasis , uncontrolled spinal cord compression , carcinomatous meningitis new evidence brain leptomeningeal disease , 5 . Patient follow abnormal laboratory test : hemoglobin &lt; 10 g/dl , absolute neutrophil count &lt; 1.5 x 109/L , platelet &lt; 100 x 109/L , AST/SGOT and/or ALT/SGPT &gt; 1.5 x upper limit normal ( ULN ) , total bilirubin &gt; 1.0 ULN , creatinine clearance &lt; 40 ml/mn ( MDRD ) , 6 . History hypersensitivity polysorbate 80 docetaxel , 7 . Contraindication use corticosteroid , 8 . Peripheral neuropathy grade ≥ 2 accord NCI CTCAE v. 4.0 , 9 . Ventricular ejection fraction &lt; 50 % ( echography scintigraphy ) , 10 . Any follow within 6 month prior study entry : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , NYHA class III IV congestive heart failure , stroke transient ischemic attack , 11 . Any follow within 3 month prior study entry : treatment resistant peptic ulcer disease , erosive esophagitis gastritis , inflammatory bowel disease , pulmonary embolism uncontrolled thromboembolic event , 12 . Other severe acute chronic medical psychiatric condition , laboratory abnormally would impart , judgment investigator , excess risk associate study participation study drug administration , , judgment investigator , would make patient inappropriate entry study , 13 . Planned vaccination live liveattenuated vaccine , 14 . Participation another clinical trial treatment investigational drug within 30 day prior randomization , 15 . Any illness problem include geographic , psychiatric psychological incompatible monitor trial 16 . Patients reproductive potential agree use effective method contraception treatment , 17 . Person deprive liberty protective custody guardianship .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Docetaxel</keyword>
	<keyword>Cabazitaxel</keyword>
</DOC>